Big pharmaceutical companies are boosting their production capacity of branded medications with billions of dollars in new U.S. manufacturing plant construction, but generic drug production still ...

The MarketWatch News Department was not involved in the creation of this content. The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031.

The MarketWatch News Department was not involved in the creation of this content. AUSTIN, Texas and TOKYO, Oct. 3, 2025 /PRNewswire/ -- According to DataM Intelligence, the Active Pharmaceutical ...

“Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world’s largest pharmaceutical market. Local API production is vital for supply chain ...

With plans to expand its domestic active pharmaceutical ingredient (API) production in the U.S., AbbVie will invest $195 million to build a new manufacturing facility in North Chicago, Illinois. This ...

Red Light Holland completes initial phase of natural psilocybin extraction using imported truffles, in collaboration with PharmAla. The optimization process seeks to refine the scalable production of ...

Lakewood, CO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL) announces that its wholly owned subsidiary, KRTL Biotech Inc., has acquired a 55% majority equity stake in Skidmore ...

(MENAFN- GlobeNewsWire - Nasdaq) The U.S. Active Pharmaceutical Ingredients (API) market is set to expand from $67.11 billion in 2024 to $117.86 billion by 2033, growing at a 6.46% CAGR. This ...

U.S. President Donald Trump issued another executive order: "Strategically stockpile the raw materials needed to make ...

Emzor Pharmaceutical Industries Limited, a leading pharmaceutical company in Nigeria, has announced a ground-breaking $230 million investment in a new Active Pharmaceutical Ingredients (API) ...

The global industry was valued at US$ 38.9 Bn in 2022 and is expected to register a CAGR of 7.1% from 2023 to 2031. Demand for biologics, biosimilars, and other biopharmaceuticals is growing at a ...